Teligent, Inc. Announces the Appointment of John Celentano as Chairman of the Board
July 20 2020 - 8:45AM
Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New
Jersey based specialty generic pharmaceutical company, is pleased
to announce that John Celentano, a current independent director of
Teligent, has been appointed Chairman of Teligent's Board of
Directors, replacing James C. Gale who opted to not stand for
reelection to Teligent’s board of directors in order to devote more
time to other business interests.
Mr. Celentano joined Teligent as a director in March 2015.
He will also continue to serve as a member of Teligent's
Compensation and Audit Committees.
Previously, Mr. Celentano held key senior leadership
positions with Bristol-Myers Squibb Company
including: President, Bristol-Myers Squibb
Healthcare Group (Mead Johnson Nutrition, ConvaTec, and
Medical Imaging); Regional President roles in Emerging Markets/Asia
Pacific, Latin America/Canada, and UK/Northern Europe; Senior
Vice President of Human Resources, Public Affairs and Philanthropy;
and Senior Vice President of Strategy and Productivity.
While at Bristol-Myers, Mr. Celentano was an active participant
in the development of their biopharma strategy and led major
initiatives on productivity transformation, streamlining operations
to support the company’s growth opportunities. Mr. Celentano
currently works as an independent senior advisor and serves on the
Board of privately held YourEncore Inc. He holds a B.A.
from the University of Delaware and an MBA
from Drexel University.
"We are excited to leverage John’s broad, extensive experience
in the pharmaceutical industry and proven boardroom leadership in
the role of Chairman of Teligent’s Board of Directors," said
Timothy B. Sawyer, Teligent's President and CEO. "We look
forward to working closely with John as our new Chairman and the
Board joins me in thanking Jim Gale for his service and wishing him
well as he focuses on his private endeavors."
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical
company. Our mission is to be a leading player in the specialty
generic prescription drug market. Learn more on our website
www.teligent.com.
Contact:
Damian FinioTeligent, Inc.856-336-9117www.teligent.com
Teligent (NASDAQ:TLGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Teligent (NASDAQ:TLGT)
Historical Stock Chart
From Jul 2023 to Jul 2024